As Vaccine Before Election Fades, Trump Falsely Touts New Drug As COVID “Cure”

US President Donald Trump shakes hands with White House Physician Rear Admiral Dr. Ronny Jackson, following his annual physical at Walter Reed National Military Medical Center in Bethesda, Maryland, January 12, 2018.... US President Donald Trump shakes hands with White House Physician Rear Admiral Dr. Ronny Jackson, following his annual physical at Walter Reed National Military Medical Center in Bethesda, Maryland, January 12, 2018. / AFP PHOTO / SAUL LOEB (Photo credit should read SAUL LOEB/AFP via Getty Images) MORE LESS

There’s a new pre-election COVID miracle in town.

Trump calls it Regeneron, though that’s the name of the company, not the drug, and claims that it not only “cured” him of COVID, but it’ll “cure” you as well.

The President has shifted from hyping a vaccine to the drug he himself was treated with: a monoclonal antibody treatment designed to prevent the virus from infecting human cells.

The huckster-in-chief’s little-noticed shift from a rushed vaccine to a new elixir comes as hopes for a pre-election vaccine began to fade this week when the FDA announced criteria for evaluating a shot that would push any approval past the November election.

“I think we should have [a vaccine] before the election, but frankly the politics gets involved,” Trump lamented in a video this week.

By Friday morning, Trump was pumping it up to Rush Limbaugh: “We have a cure. More than just a therapeutic, we have a cure.”

Regeneron’s cutting-edge drug isn’t a vaccine, nor is it a cure. It’s a treatment, and one that remains unproven, though promising.

But that hasn’t stopped Trump from touting it, and making himself Exhibit A for the false proposition that it’s a cure.

Presidential son Eric Trump went so far on Wednesday in a Georgia talk radio interview to describe Regeneron’s drug as a vaccine, saying that “there’s never been vaccines created so quickly.”

“My father was just on one of them,” he added. “It knocked it out in 24 hours.”

The actual drug is an experimental treatment that, scientists say, holds high hopes treating COVID patients. Regeneron asked the FDA for emergency approval on Thursday, while Eli Lilly, which has a similar treatment, asked for the same emergency authorization on Wednesday.

The FDA has yet to verify data around the new drugs, and they have yet to undergo large-scale trials proving that they work safely.

Within a day of the FDA announcing that it would use criteria to evaluate a COVID vaccine that would push its approval until after the November elections, Trump and his advisers began to pressure the FDA to accelerate approval of the Regeneron treatment.

The Washington Post reported that both the President and Chief of Staff Mark Meadows have been pressuring FDA head Stephen Hahn to approve the emergency use petitions from Regeneron and Eli Lilly.

Trump also told Limbaugh on Friday that “hundreds of thousands of vials [of Regeneron’s antibody treatment] are being sent to hospitals around the country.”

That appears to be a Trumpian version of an announcement that officials with Operation Warp Speed, the administration’s vaccine development program, made on a Friday morning press call.

On the call, Warp Speed official Paul Mango said that the government had bought “a couple of hundred thousand” doses of the drugs, and would have 1 million ready to go by the end of the year for distribution, should they prove effective.

It’s not entirely clear why Trump thinks the drug is so effective.

Some of the government’s top advisers have repudiated him, including Dr. Tony Fauci, who told MSNBC on Thursday that “when you only have one, you can’t make the determination that that’s a cure.”

“You have to do a clinical trial involving a large number of individuals compared either to a placebo or another intervention,” he said.

Dear Reader,

When we asked recently what makes TPM different from other outlets, readers cited factors like honesty, curiosity, transparency, and our vibrant community. They also pointed to our ability to report on important stories and trends long before they are picked up by mainstream outlets; our ability to contextualize information within the arc of history; and our focus on the real-world consequences of the news.

Our unique approach to reporting and presenting the news, however, wouldn’t be possible without our readers’ support. That’s not just marketing speak, it’s true: our work would literally not be possible without readers deciding to become members. Not only does member support account for more than 80% of TPM’s revenue, our members have helped us build an engaged and informed community. Many of our best stories were born from reader tips and valuable member feedback.

We do what other news outlets can’t or won’t do because our members’ support gives us real independence.

If you enjoy reading TPM and value what we do, become a member today.

Latest Muckraker
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Associate Editor:
Investigations Desk:
Director of Audience:
Editor at Large:
General Counsel:
Head of Product:
Director of Technology:
Associate Publisher:
Front End Developer:
Senior Designer: